Special Drug Use Investigation of Xarelto [SPAF].

Trial Profile

Special Drug Use Investigation of Xarelto [SPAF].

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Acronyms XAPASS
  • Sponsors Bayer
  • Most Recent Events

    • 29 Aug 2016 According to a Bayer media release, the company presented data from this study at European Society of Cardiology (ESC) 2016.
    • 13 Nov 2015 Planned End Date changed from 1 Jan 2020 to 1 Mar 2019, as reported by ClinicalTrials.gov.
    • 13 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top